Katherine Huppler Hullsiek, Ph.D.

Senior Research Associate
Division of Biostatistics
School of Public Health

2221 University Ave SE, Suite 200
Minneapolis, Minnesota 55414

Phone: (612) 626-0314
Fax: (612) 626-8892
email: hulls003@umn.edu

My research interests include the design, conduct, and analysis of HIV-related clinical trials and the analysis of longitudinal cohort data related to AIDS research. I am a biostatistician with INSIGHT, an international HIV clinical trials network, and several other grant-funded AIDS clinical trials. I am also the senior biostatistician for the Cryptococcal Optimal ART Timing (COAT) study, which is currently enrolling participants at 3 African sites.

Papers

• Huppler Hullsiek K, Grund B. Considerations for endpoint selection when designing HIV clinical trials. Current Infectious Disease Disease Reports, 2011. DOI 10.1007/s11908-011-0231-7.

• Chun HM, Roediger MP, Huppler Hullsiek K, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML. Hepatitis B virus co-infection negatively impacts HIV outcomes in HIV seroconverters. Journal of Infectious Diseases, 2012: 205:185-193.

• Li JZ, Paredes R, Ribaudo HF, Svarovskaia ES, Kozal MJ, Huppler Hullsiek K, Miller MD, Bangsberg D, Kuritzkes D. Relationship between minority NNRT resistance mutations, adherence, and risk of virologic failure. AIDS, 2012: 26(2):185-192.

• Krantz EM, Huppler Hullsiek K, Okulicz JF, Weintrob AC, Agan BK, Crum-Cianflone NF, Ganesan A, Ferguson TM, HAle BR. Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. JAIDS, 2011: 57(5);396-403.

• Li JZ, Paredes R, Ribaudo HF, Svarovskaia ES, Metzner KJ, Kozal MJ, Huppler Hullsiek K, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes D. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure. Journal of the American Medical Association, 2011: 305(13);1327-1335.

• Boulware DR, Huppler Hullsiek K, Puronen CE, Rupter A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I. Higher levels of CRP, D-dimer, IL-6 and hyaluronic acid before initiation of antiretroviral therapy are associated with increased risk of AIDS or death. Journal of Infectious Diseases, 2011: 203;1637-1646.

• Landrum ML, Huppler Hullsiek K, Chun HM, Crum-Cianflone NF, Ganesan A, Weintrob AC, Barthel V, Agan BK. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis influences the risk of HBV infection following HIV diagnosis. American Journal of Epidemiology, 2011: 173(1);84-93.

• Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, Ganesan A, Landrum M, Weintrob A, Again B, Medina S, Rahkola J, Hale B, Janoff EN. The association of ethnicity with anitibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine; 2010: 28;7583-7588.

• Huppler Hullsiek K, George M, Brown SK. Designing and managing a flexible and dynamic biorepository system: A 15 year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networks. Current Opinion in HIV and AIDS, 2010; 5(6): 538-544.

• Crum-Cianflone NF, Huppler Hullsiek K, Ganesan A, Weintrob A, Okulicz J, Agan BK. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? AIDS 2010; 24(18):2881-2883.

• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum M, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine (PCV) to polysaccharide vaccine (PPV) among HIV-infected adults. JID 2010; 202:1114-1125.

• Baker JV, Quick H, Huppler Hullsiek K, Tracy R, Duprez D, Henry K, Neaton JD. IL-6 and D-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Medicine 2010; 11(9):608-609.

• Gardner EM, Huppler Hullsiek K, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class-specific resistance in a large prospective clincial trial. AIDS 2010;24(3):395-403.

• Chun HM, Fieberg AM, Huppler Hullsiek K, Lifson AF, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML. The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Clinical Infectious Disases, 2010; 50(3):426-436.

• Baker J, Ayenew W, Quick H, Huppler Hullsiek K, Tracy R, Henry K, Duprez D, Neaton JD. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. Journal of Infectious Diseases, 2010; 201:285-292.

• Crum-Cianflone NF, Huppler Hullsiek K, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS, 2010; 24(4):535-543..

• Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel V, O'Connell RJ, Fieberg A, Chun HM, Marconi VC, Dolan MJ, Agan BK. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS, 2010; 24(4):545-555.

• Baker JV, Duprez D, Rapkin J, Huppler Hullsiek K, Quick H, Grimm R, Neaton JD, Henry K. Untreated HIV infection and large and small artery elasticity. JAIDS, 2009; 52(1):25-31.

• Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, Peel S, Agan BK. Hepatitis B vaccine response in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine, 2009; 27:4731-4738.

• Crum-Cianflone N, Huppler Hullsiek K, Satter E, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan B. Cutaneous malignancies among HIV-infected persons. Archives of Internal Medicine, 2009; 169(12):1130-1138.

• Crum-Cianflone N, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Poehlman Roediger M, Agan B, Wegner s. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. JAIDS, 2009; 51(3):305-309.

• Simen B, Simons JF, Huppler Hullsiek K, Novak RM, MacArthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. Low abundance drug resistant variants in chronically HIV-infected antiretroviral naive patients significnatly impact treatment outcome. Journal of Infectious Diseases, 2009;199:693-701.

• Crum-Cianflone NC, Huppler Hullsiek K, Marconi V, Weintrob A, Ganesan A, Barthel V, Fraser S, Agan B, Wegner S. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20 year cohort study. AIDS, 2009; 23:41-50 .

• van den Berg-Wolf M, Huppler Hullsiek K, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, MacArthur RD. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1 infected persons. HIV Clinical Trials, 2008; 9:324-336.

• Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Huppler Hullsiek K, Stephan C, Lundgren J. Viral resuppression and detection of drug resistance following interruption of a suppressive NNRTI-based regimen. AIDS, 2008; 22(17):2279-2289.

• Mannheimer SB, Wold N, Gardner EM, Telzak EE, Huppler Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected indivuals. Clinical Infectious Diseases, 2008; 46(6):941-5.

• Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G. A randomized comparison of two instruments for measuring self-reported adherence. AIDS Care, 2008; 20(2):161-169.

• Gardner EM, Sharma S, Peng G, Huppler Hullsiek K, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to components of combination antiretroviral therapy is associated with virologic failure and antiretroviral resistance. AIDS, 2008; 22:75-82.

• Kozal MJ, Huppler Hullsiek K, MacArthur RD, van den Berg-Wolf M, Peng G, Xiang Y, Baxter JD, Uy J. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clinical Trials, 2007; 8:357-370.

• MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Huppler Hullsiek K, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet, 2006; 368:2125-2135.

• Lawrence J, Huppler Hullsiek K, Thackeray L, Abrams D, Crane L, Mayers D, Jones M, Saldanha J, Schmetter B, Baxter J. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final results of the CPCRA 064 Study. Journal of Acquired Immune Deficiency Syndromes, 2006; 43:169-178.

• Kozal M, Huppler Hullsiek K, Leduc R, Novak R, MacArthur R, Lawrence J, Baxter J. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients enrolling in clinical trials. Antiviral Therapy, 2006; 11:457-463.

• Novak R, Chen L, MacArthur R, Baxter J, Huppler Hullsiek K, Peng G, Xiang Y, Henley C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M, and the Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically human immunodeficiency virus-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clinical Infectious Diseases, 2005; 40:468-474.

• Lawrence J, Mayers D, Huppler Hullsiek K, Collins G, Abrams D, Reisler R, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. Structured treatment interruption in patients with multi-drug resistant Human immunodeficiency Virus. New England Journal of Medicine , 2003; 349:837-846.

• Tedaldi E, Huppler Hullsiek K, Malvestutto C, Arduino R, Fisher E, Gaglio P, Jenny-Avital E, McGowan J, Perez G. Prevalence and characteristics of HCV coinfection in an HIV clinical trials group. Clinical Infectious Diseases. 2003; 36:1313-1317.

• Han C., Pulling CC, Telke SE, Huppler Hullsiek K. Assessing the utility of five domains in the SF-12 Health Status questionnaire in an AIDS clinical trial. AIDS , 2002; 16:431-439.

• Huppler Hullsiek K,, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics. 2002; 4:179-193.

Other Links

Mandatory statement:

"The views and opinions expressed in this page are strictly those of the page author.
The contents of this page have not been approved by the University of Minnesota."